Welcome to our dedicated page for Merck & news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & stock.
Merck & Co., Inc. reports news across a global pharmaceutical business known as MSD outside the United States and Canada. Company updates center on human health products for areas such as oncology, cardiometabolic disease and infections; vaccines including Gardasil; and Merck Animal Health medicines, devices and customer-support systems.
Recurring developments include FDA approvals, clinical and regulatory disclosures, research publications, pipeline additions, business development transactions, material agreements, capital-structure updates, governance matters, and operating and financial results. Recent themes include the approved HIV-1 regimen IDVYNSO, investigational programs such as enlicitide decanoate and TERN-701, technology partnerships for research, manufacturing and commercial functions, and animal health digital engagement initiatives.
Merck Animal Health, a division of Merck & Co. (NYSE:MRK), launched a global campaign on World Rabies Day, September 28, to raise awareness about rabies prevention through dog vaccination. Partnering with Mission Rabies and Rabies Free Africa, the initiative emphasizes the importance of vaccinating dogs, which can save both canine and human lives. With an estimated 59,000 human deaths from rabies annually, mainly from dog bites, the campaign aims for a 70% vaccination rate in endemic areas. Merck has donated over three million rabies vaccine doses to support the WHO’s "Zero by 2030" goal.
TriRx Pharmaceutical Services has confirmed the acquisition of a manufacturing site from MSD Sante Animale, part of Merck & Co. (NYSE:MRK), located in Segré, France. This strategic move aims to enhance TriRx's global CDMO presence, ensuring continued supply of veterinary products. The facility, staffed by over ninety employees, is equipped for sterile suspensions and ointments, aligning with TriRx's growth in the animal health market. The agreement includes a long-term supply commitment and has received all necessary regulatory approvals, further positioning TriRx as a leader in contract manufacturing.